Skip to main content
CSL Behring Joins Together With Others Around the World—Sponsoring the 2017 Meeting of the European Society for Immunodeficiencies (ESID)
Biotherapeutics leader to map attendee visits to result in a donation to International Patient Organisation for Primary Immunodeficiencies (IPOPI)

EDINBURGH, Scotland — 06 September 2017

Global biotherapeutics leader CSL Behring today announced that as part of its participation as a platinum sponsor of the 2017 meeting of the European Society for Immunodeficiencies (ESID) it will host an industry symposium, support several scientific posters and encourage attendees to log their home-location on a world map to be counted towards a donation to IPOPI, the International Patient Organisation for Primary Immunodeficiencies.

"Our presence at this year’s ESID meeting revolves around our patient focus," said Karen MacPhail, Senior Director, Immunology, CSL Behring. "Part of that commitment is our promise to share clinical findings that advance immunoglobulin research and foster dialogues around new developments, like those at our symposium."

Tuesday’s satellite symposium "New developments in secondary antibody deficiency: How to investigate and treat" (12 September, 12:45, Pentland Suite, EICC) will be chaired by Mikko Seppänen (Helsinki University Hospital) and include experts Smita Patel (John Radcliffe Hospital), Javier Carbone (Hospital General Universitario Gregorio Marañón), and Stephen Jolles (Hospital of Wales) addressing:

  • Current investigation and treatment of secondary antibody deficiency (Patel)
  • Heart transplant-related secondary antibody deficiency: a new frontier (Carbone)
  • New secondary antibody deficiencies: a look to the future (Jolles)

CSL Behring's exhibition booth theme is "Join together around the world to treat immunodeficiencies" and will highlight the emotional journey undertaken by patients, physicians and caregivers. When visiting booth #5, attendees will be invited to register an electronic pin on a world map showing where they have travelled from. For each pin placed on the map, CSL Behring will make a donation to IPOPI.

In addition, several posters summarizing research supported by CSL Behring will be presented at the meeting, including:

  • Infections seasonality in PID (Rojavin and Lawo) Poster #0052
  • Haemolytic anaemia with IVIG in PID and ITP: effect of anti-A donor screening (Martinez, et al) Poster #0053
  • Biweekly SCIG: The IBIS study (Cupone, et al) Poster #0117

About Primary and Secondary Immunodeficiencies
Immunodeficiencies constitute a group of more than 150 diseases that affect the cells, tissues and proteins of the immune system. In people with primary or secondary immunodeficiency, certain components of the immune system are either absent or functioning inadequately, leaving them more susceptible to infection. In children, especially, infections may not improve with treatment as expected and may keep returning. As a result, patients may face repeated rounds of antibiotics and hospitalization for treatment. Repeated infections can lead to organ damage, which, over time, can become life threatening.

About CSL Behring
CSL Behring is a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients' needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent haemolytic disease of the newborn.

CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL), headquartered in Melbourne, Australia, employs nearly 20,000 people, delivering its life-saving therapies to people in more than 60 countries. For more information visit and follow us on

# # #

Media Contact
Jennifer Purdue
Office: +1 610 878 4802
Mobile: +1 610 306 9355

Get our latest news releases in your inbox
* Required Fields